Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oph1
- Development stage
- Phase 1
- Administration
- Ophthalmic
01
Overview
Oph1 is referenced as an investigational drug that was evaluated in a Phase 0 clinical trial for tolerability compared to Restasis (cyclosporine) in healthy volunteers. The available information does not specify its mechanism of action, molecular target, or therapeutic indication beyond the context of this feasibility study. There is no evidence from the provided sources that it has reached advanced clinical development or approval for any disease[1].
- Other names
- Oph1Oph-1Oph 1
Beyond the preview
Go deeper on Oph1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oph1.